MUMBAI (Reuters) - Generic drugmaker Ranbaxy Laboratories Ltd, which is in the process of being acquired by larger rival Sun Pharmaceutical Industries Ltd, reported a profit in its second quarter.
The company posted a profit of 4.78 billion rupees ($78 million), compared with a loss of 4.5 billion rupees a year earlier, when it took a foreign exchange charge of 3.6 billion rupees.
($1 = 61.3100 rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Prateek Chatterjee)